FOXO4-DRI price, and what it is not being compared against
The number is simple: $199.99 list, $134.00 current, $67.00 with the code applied. What is missing is everything a price on this site is normally compared against.
There is no insurance copay, because no insurer covers an unapproved compound. There is no pharmacy cash price, because no pharmacy stocks it. There is no telehealth programme fee, because no prescriber will write for it. FOXO4-DRI holds no marketing authorisation from the FDA, the EMA or the MHRA, and that single fact removes every comparator this site usually provides.
What is left is a research-supply price and, for those who go looking, a clinic price. The gap between them is the consumer-protection story.
| Line | Figure | Comparator on an approved drug |
|---|---|---|
| List price | $199.99 | Manufacturer list |
| Current price | $134.00 | Pharmacy cash price |
| With code PEPTIDEDECK | $67.00 | Copay after insurance |
| Per mg at labelled 10 mg | $6.70 | Cost per dose |
| Insurance contribution | None possible | Formulary tier |
| Prescriber fee | None, none exists | Consultation or telehealth fee |
The price, and the comparators that do not exist
What a longevity clinic charges for the same thing
Clinics marketing senolytic programmes do not publish standardised pricing, and the packages vary enough that a single figure would be misleading. What can be said is where the material comes from.
No clinic has access to a supply chain that a research-peptide buyer does not. There is no approved FOXO4-DRI product for a clinic to purchase through a pharmaceutical wholesaler, because none exists. A clinic offering this compound is buying from the same category of supplier, and frequently cannot produce documentation beyond the same vendor certificate a buyer could download themselves.
The premium therefore purchases the clinical setting, the consultation, and the implied endorsement. It does not purchase a better-characterised product, a regulated supply chain, or any evidence that the compound works.
That is the honest framing, and it applies regardless of how professional the presentation is.
Why cost per milligram is not a clean comparison here
Even the research-supply price resists a simple per-milligram figure, and the reason is unusual.
The vendor publishes two certificates from two laboratories covering two different batches, and they disagree about how much peptide is in the vial. One assayed 11.41 mg, the other 8.30 mg, both against a 10 mg label. Both tested above 99% pure, because purity and quantity are separate measurements.
So the real cost per milligram moves by roughly 37% depending on which batch shipped. That is disclosed only because this vendor measures fill at all, which most do not. A supplier quoting a confident single figure is quoting the label.
| Batch | Assayed content | Cost per mg at $67.00 |
|---|---|---|
| Kovera 55-05260628 | 11.41 mg | About $5.87 |
| Label assumption | 10 mg | $6.70 |
| MZ Biolabs 55-01260229 | 8.30 mg | About $8.07 |
Cost per milligram by assayed batch
What you are actually paying for
Set against an approved medicine, the gap is wider than any price comparison suggests.
There is no prescriber assessing suitability, no label, no approved indication, no established dose, no adverse-event reporting route and no manufacturer liability. FOXO4-DRI has never been administered to a person in a registered clinical trial, so the evidence that normally sits behind all of that does not exist.
Its efficacy record is entirely preclinical. The 2017 study in Cell reported restored fitness, fur density and renal function in aged mice, which is a genuine finding in mice. A 2023 study in Circulation separately found that clearing senescent cells could promote pulmonary hypertension, so even the direction of effect is unsettled.
Our affiliate disclosure explains how we are paid, and the NAD source comparison applies the same reasoning to a compound where fill variance is easier to see.